

EFFECTIVE DATE: 11 | 10 | 2016

POLICY LAST UPDATED: 08 | 06 | 2019

OVERVIEW

This policy describes coverage of molecular testing using the PathfinderTG system.

MEDICAL CRITERIA

BlueCHiP for Medicare

The specific requirements for medical necessity involve:

1. Highly-concise affirmation, documented in the medical record, that a decision regarding treatment has not already been made and that the results of the molecular evaluation will assist in determining if more aggressive treatment than what is being considered is necessary.
2. Previous first-line diagnostics, such as, but not restricted to, the following have demonstrated:
 - a. A pancreatic cyst fluid carcinoembryonic antigen (CEA), which is greater than or equal to 200 ng/ml, suggesting a mucinous cyst, but is not diagnostic.
 - b. Cyst cytopathologic or radiographic findings, which raise the index of malignancy suspicion, but where second-line molecular diagnostics is expected to be more compelling in the context of a surgical vs. non-surgical care plan.

PRIOR AUTHORIZATION

BlueCHiP for Medicare

Prior authorization is required and is obtained via the online tool for participating providers. See the Related Policies section.

Commercial Products

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare

PathfinderTG molecular testing is covered for pancreatic cyst/mass when the medical criteria are met. All PathfinderTG® indications other than pancreatic cyst fluid evaluation are considered not covered due to insufficient data on both analytical and clinical validity.

Note: BCBSRI must follow CMS (Centers for Medicare and Medicaid Services) guidelines, such as National Coverage Determinations or Local Coverage Determinations for all BlueCHiP for Medicare policies. Therefore, BlueCHiP for Medicare policies may differ from Commercial Products. In some instances, benefits for BlueCHiP for Medicare may be greater than what is allowed by the CMS.

Commercial Products

Molecular testing using the PathFinderTG system is considered not medically necessary for all indications including the evaluation of pancreatic cyst fluid, Barrett esophagus, and solid pancreaticobiliary lesions as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for services not medically necessary.

BACKGROUND

Commercial

Topographic genotyping, also called molecular anatomic pathology, integrates microscopic analysis (anatomic pathology) with molecular tissue analysis. Under microscopic examination of tissue and other specimens, areas of interest may be identified and microdissected to increase tumor cell yield for subsequent molecular analysis. Topographic genotyping may permit pathologic diagnosis when first-line analyses are inconclusive.

RedPath Integrated Pathology (now Interpace Diagnostics) has patented a proprietary platform called PathFinderTG; it provides mutational analyses of patient specimens. The patented technology permits analysis of tissue specimens of any size, “including minute needle biopsy specimens,” and any age, “including those stored in paraffin for over 30 years.” Interpace currently describes PathFinderTG test called PancaGEN on its website and describes another PathFinder test called BarreGEN™ “as in a “soft launch”. As stated on the company website, PancaGEN integrates molecular analyses with first-line results (when these are inconclusive) and pathologist interpretation. The manufacturer calls this technique integrated molecular pathology. Test performance information is not provided on the website.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Patented diagnostic tests (eg, PancaGEN™) are available only through Interpace Diagnostics (Pittsburgh, PA and New Haven, CT; formerly RedPath Integrated Pathology) under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

For individuals who have pancreatic cysts who do not have a definitive diagnosis after first-line evaluation and who receive standard diagnostic and management practices plus topographic genotyping (PancaGEN molecular testing), the evidence includes retrospective studies of clinical validity and clinical utility. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, morbid events, and quality of life. The best evidence regarding incremental clinical validity comes from the National Pancreatic Cyst Registry report that compared PancaGEN performance characteristics with current international consensus guidelines and provided preliminary but inconclusive evidence of a small incremental benefit for PancaGEN. The analyses from the registry study included only a small proportion of enrolled patients, relatively short follow-up time for observing malignant transformation, and limited data on cases where the PancaGEN results are discordant with international consensus guidelines. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have Barrett esophagus who receive standard prognostic techniques plus topographic genotyping (BarreGEN molecular testing), the evidence includes a systematic review. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, morbid events, and quality of life. The systematic review identified no studies relevant to this evidence review. Two observational studies were excluded based on selection criteria because it was unclear whether the test used was specifically BarreGEN or whether the BarreGEN prognostic algorithm was applied for classification. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have solid pancreaticobiliary lesions who do not have a definitive diagnosis after first-line evaluation and who receive standard diagnostic and management practices plus topographic genotyping (PancaGEN molecular testing), the evidence includes 3 observational studies of clinical validity. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, morbid events,

and quality of life. Two of the 3 studies had populations with biliary strictures and the other had a population of patients with solid pancreaticobiliary lesions. The studies reported higher sensitivities and specificities when PancaGEN testing was added to cytology results compared with cytology alone. However, the inclusion of patients in the analysis who may not have solid pancreaticobiliary lesions (those with biliary strictures not caused by solid pancreaticobiliary lesions) limits the interpretation of the results. While preliminary results showed a potential incremental benefit for PancaGEN, further research focusing on patients with solid pancreaticobiliary lesions is warranted. The evidence is insufficient to determine the effects of the technology on health outcomes.

BlueCHiP for Medicare

PathfinderTG® will be considered medically reasonable and necessary when selectively used as an **occasional second-line diagnostic supplement**:

- only where there remains clinical uncertainty as to either the current malignancy or the possible malignant potential of the pancreatic cyst based upon a comprehensive first-line evaluation; **AND**
- a decision regarding treatment (e.g. surgery) has NOT already been made based on existing information.

DOCUMENTATION REQUIREMENTS

1. All documentation must be maintained in the patient's medical record and made available to the contractor upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service(s)). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
3. The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
4. The medical record documentation must support the medical necessity of the services as directed in this policy.
5. The medical record must clearly indicate the purpose of the Pathfinder TG® test.
6. The medical record should clearly support why and how the first-line diagnostic work-up was insufficient to adequately monitor or manage the pancreatic cyst(s) under evaluation, such that this very specialized second-line PathfinderTG®testing has become necessary.

CODING

BlueCHiP for Medicare and Commercial Products

There is no established CPT or HCPCS code which adequately describes the procedure; therefore, it may be reported using an unlisted CPT code (84999 or 81479)

RELATED POLICIES

Genetic Testing Services
Unlisted Procedures

PUBLISHED

Provider Update, October 2019
Provider Update, January 2019
Provider Update, November 2017
Provider Update, December 2016
Provider Update, January 2016
Provider Update, January 2015
Provider Update, September 2013
Provider Update, June 2012

REFERENCES

1. CMS.gov Centers for Medicare and Medicaid Service Local Coverage Determination (LCD): Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG ® (L34864)

2. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatol.* Dec 2006;6(1-2):17-32. PMID 16327281
3. Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology.* Apr 2015;148(4):819-822; quiz 812-813. PMID 25805375
4. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and delphi consensus for management of Barrett's Esophagus with no dysplasia, indefinite for, or low-grade dysplasia. *Am J Gastroenterol.* May 2015;110(5):662-682; quiz 683. PMID 25869390
5. Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: diagnosis and management of Barrett's esophagus. *Am J Gastroenterol.* Jan 2016;111(1):30-50; quiz 51. PMID 26526079
6. Trikalinos T, Terasawa T, Raman G, et al. *Technology Assessment: A systematic review of loss-of-heterozygosity based topographic genotyping with PathfinderTG®.* Rockville, MD: Agency for Healthcare Research and Quality;2010.
7. U.S. Patent #7,014,999. Finkelstein et al. March 21, 2006. Topographic genotyping. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=16&f=G&l=50&d=PTXT&S1=\(redpath+AND+specimen\)&OS=redpath+AND+specimen&RS=\(redpath+AND+specimen\).](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=16&f=G&l=50&d=PTXT&S1=(redpath+AND+specimen)&OS=redpath+AND+specimen&RS=(redpath+AND+specimen).) Accessed August 30, 2018.
8. Interpace Diagnostics. Advancing patient care through molecular diagnostic testing. 2016; <http://www.interpacediagnostics.com/>. Accessed August 30, 2018
9. Interpace Diagnostics. How PancreGEN works. 2016; <http://www.interpacediagnostics.com/pancragen/how-it-works/>. Accessed August 30, 2018.
10. de Oliveira PB, Puchnick A, Szejnfeld J, et al. Prevalence of incidental pancreatic cysts on 3 tesla magnetic resonance. *PLoS One.* Mar 23 2015;10(3):e0121317. PMID 25798910
11. Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. *AJR Am J Roentgenol.* Sep 2008;191(3):802-807. PMID 18716113
12. de Jong K, Nio CY, Hermans JJ, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. *Clin Gastroenterol Hepatol.* Sep 2010;8(9):806-811. PMID 20621679
13. Gardner TB, Glass LM, Smith KD, et al. Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults. *Am J Gastroenterol.* Oct 2013;108(10):1546-1550. PMID 24091499
14. Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. *Am J Gastroenterol.* Oct 2007;102(10):2339-2349. PMID 17764489
15. Oh HC, Kim MH, Hwang CY, et al. Cystic lesions of the pancreas: challenging issues in clinical practice. *Am J Gastroenterol.* Jan 2008;103(1):229-239; quiz 228, 240. PMID 18076739
16. Scheiman JM, Hwang JH, Moayyedi P. American Gastroenterological Association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology.* Apr 2015;148(4):824-848 e822. PMID 25805376
17. Interpace Diagnostics. Clinical utility. 2016; <http://www.interpacediagnostics.com/pancragen/clinical-utility/>. Accessed August 30, 2018.
18. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. *Endoscopy.* Feb 2015;47(2):136-142. PMID 25314329
19. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. *Clin Gastroenterol Hepatol.* Oct 2005;3(10):967-973. PMID 16234041
20. Khalid A, Nodit L, Zahid M, et al. Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. *Am J Gastroenterol.* Nov 2006;101(11):2493-2500. PMID 17029619
21. Kushnir VM, Mullady DK, Das K, et al. The diagnostic yield of malignancy comparing cytology, fish, and molecular analysis of cell free cytology brush supernatant in patients with biliary strictures undergoing endoscopic retrograde cholangiography (ERC): a prospective study. *J Clin Gastroenterol.* Aug 13 2018. PMID 30106834

22. Gonda TA, Viterbo D, Gausman V, et al. Mutation profile and fluorescence in situ hybridization analyses increase detection of malignancies in biliary strictures. *Clin Gastroenterol Hepatol*. Jun 2017;15(6):913-919 e911. PMID 28017843
23. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. *Gastroenterology*. Mar 2011;140(3):e18-52; quiz e13. PMID 21376939
24. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 2.2018.
https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed August 30, 2018..
25. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers. Version 1.2018.
https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed August 30, 2018..
26. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Version 2.2018.
https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed August 30, 2018..
27. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 3.2018.
https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed August 30, 2018..
28. Tempero, MM. NCCN Guidelines Updates: Pancreatic Cancer.. *J Natl Compr Canc Netw*, 2019 May 23;17(5.5). PMID 31117041.
29. Benson, AA, D'Angelica, MM, Abbott, DD. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.. *J Natl Compr Canc Netw*, 2019 Apr 9;17(4). PMID 30959462.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

